X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2292) 2292
Publication (297) 297
Newsletter (55) 55
Book Chapter (25) 25
Book Review (7) 7
Book / eBook (4) 4
Conference Proceeding (3) 3
Dissertation (3) 3
Magazine Article (1) 1
Newspaper Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1971) 1971
index medicus (947) 947
animals (783) 783
female (616) 616
oncology (607) 607
male (591) 591
mice (492) 492
lymphomas (455) 455
hematology (445) 445
cancer (441) 441
apoptosis (395) 395
cell line, tumor (381) 381
middle aged (365) 365
adult (347) 347
lymphoma (347) 347
expression (302) 302
lymphoma, large b-cell, diffuse - enzymology (294) 294
aged (286) 286
cell biology (276) 276
tumor cells, cultured (265) 265
lymphoma, b-cell - enzymology (247) 247
b-lymphocytes - enzymology (246) 246
lymphoma - enzymology (242) 242
activation (238) 238
leukemia (238) 238
biochemistry & molecular biology (237) 237
phosphorylation (236) 236
research (223) 223
apoptosis - drug effects (218) 218
immunology (215) 215
proteins (207) 207
hemic and lymphatic diseases (206) 206
pathology (202) 202
adolescent (192) 192
immunohistochemistry (191) 191
cell line (187) 187
child (187) 187
signal transduction (183) 183
genetic aspects (181) 181
gene expression (180) 180
research article (171) 171
antineoplastic agents - pharmacology (167) 167
prognosis (163) 163
mutation (160) 160
analysis (158) 158
lymphoma, large b-cell, diffuse - pathology (156) 156
lymphoma, non-hodgkin - enzymology (155) 155
lymphoma, b-cell - pathology (153) 153
kinases (149) 149
protein-tyrosine kinases - metabolism (147) 147
precursor cell lymphoblastic leukemia-lymphoma - enzymology (146) 146
multidisciplinary sciences (142) 142
article (141) 141
enzymes (140) 140
antineoplastic agents - therapeutic use (129) 129
gene (128) 128
health aspects (128) 128
protein kinase inhibitors - pharmacology (128) 128
medicine (126) 126
non-hodgkins-lymphoma (126) 126
tumors (126) 126
gene expression regulation, neoplastic (124) 124
non-hodgkin's lymphomas (123) 123
aged, 80 and over (120) 120
acute lymphoblastic-leukemia (119) 119
child, preschool (117) 117
b-lymphocytes - immunology (116) 116
signal transduction - drug effects (116) 116
base sequence (115) 115
chemotherapy (113) 113
genes (112) 112
b-cell lymphoma (111) 111
chronic lymphocytic-leukemia (110) 110
enzyme activation (110) 110
leukemia - enzymology (110) 110
physiological aspects (110) 110
lymphocytes (109) 109
care and treatment (108) 108
molecular sequence data (108) 108
neoplasms - enzymology (105) 105
cells (104) 104
leukemia, lymphocytic, chronic, b-cell - enzymology (104) 104
burkitt lymphoma - enzymology (103) 103
cell proliferation - drug effects (101) 101
pharmacology & pharmacy (101) 101
lymphoma, b-cell - genetics (100) 100
nf-kappa-b (100) 100
gene-expression (99) 99
science (99) 99
enzyme inhibitors - pharmacology (98) 98
caspases - metabolism (97) 97
cell proliferation (96) 96
medicine, research & experimental (96) 96
survival (96) 96
cell cycle (95) 95
flow cytometry (95) 95
hodgkin disease - enzymology (93) 93
lymphoma, large b-cell, diffuse - genetics (92) 92
protein-tyrosine kinases - genetics (92) 92
protein-tyrosine kinases - antagonists & inhibitors (91) 91
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2293) 2293
Russian (22) 22
German (15) 15
Chinese (5) 5
French (5) 5
Japanese (4) 4
Hungarian (2) 2
Italian (2) 2
Romanian (2) 2
Spanish (2) 2
Danish (1) 1
Polish (1) 1
Serbian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nature, ISSN 0028-0836, 03/2011, Volume 471, Issue 7337, pp. 189 - 196
B-cell non-Hodgkin's lymphoma comprises biologically and clinically distinct diseases the pathogenesis of which is associated with genetic lesions affecting... 
CBP | RUBINSTEIN-TAYBI SYNDROME | HISTONE ACETYLTRANSFERASES | ACETYLATION | P300 | MULTIDISCIPLINARY SCIENCES | CREB-BINDING-PROTEIN | CYCLE ARREST | ACUTE MYELOID-LEUKEMIA | TRANSCRIPTIONAL COACTIVATOR | P53 | Histone Acetyltransferases - deficiency | Recurrence | Acetyltransferases - metabolism | Histone Acetyltransferases - chemistry | Humans | E1A-Associated p300 Protein - genetics | Gene Expression Regulation, Neoplastic | Histone Acetyltransferases - genetics | CREB-Binding Protein - chemistry | E1A-Associated p300 Protein - metabolism | Lymphoma, B-Cell - genetics | Acetyltransferases - genetics | Mutation, Missense - genetics | CREB-Binding Protein - genetics | DNA-Binding Proteins - metabolism | CREB-Binding Protein - metabolism | Lymphoma, Follicular - genetics | Acetyltransferases - deficiency | Base Sequence | Histone Acetyltransferases - metabolism | Lymphoma, B-Cell - enzymology | HEK293 Cells | Acetylation | CREB-Binding Protein - deficiency | Lymphoma, Large B-Cell, Diffuse - pathology | Lymphoma, Follicular - pathology | Cells, Cultured | E1A-Associated p300 Protein - chemistry | Lymphoma, Large B-Cell, Diffuse - enzymology | Tumor Suppressor Protein p53 - metabolism | Protein Structure, Tertiary - genetics | Mutation - genetics | Acetyl Coenzyme A - metabolism | Acetyltransferases - chemistry | Animals | Lymphoma, B-Cell - pathology | Polymorphism, Single Nucleotide - genetics | Protein Binding | Lymphoma, Follicular - enzymology | Mice | E1A-Associated p300 Protein - deficiency | Lymphoma, Large B-Cell, Diffuse - genetics | Proto-Oncogene Proteins c-bcl-6 | Sequence Deletion - genetics | Lymphomas | Genetic aspects | B cells | Gene mutations | Health aspects | Abnormalities | Proteins | Congenital diseases | Pathogenesis | Genes | Cell cycle | Genomes | Genetic engineering | Mutation | Binding sites
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 7/2010, Volume 107, Issue 29, pp. 13075 - 13080
Activation of the B-cell antigen receptor (BCR) signaling pathway contributes to the initiation and maintenance of B-cell malignancies and autoimmune diseases.... 
T lymphocytes | Animal models | Disease models | Gels | B lymphocytes | B cell lymphoma | Arthritis | Mice | Autoimmune diseases | Tumors | X-linked agammaglobulinemia | Lymphoma | COLLAGEN-INDUCED ARTHRITIS | THERAPY | RITUXIMAB | MULTIDISCIPLINARY SCIENCES | lymphoma | DOGS | FAMILY KINASES | BTK | RECEPTOR | DEPLETION | MICE | Arthritis, Experimental - drug therapy | Pyrazoles - therapeutic use | Humans | Benzofurans - administration & dosage | Benzofurans - pharmacology | Autoantibodies - biosynthesis | Pyrimidines - chemistry | Benzofurans - chemistry | Protein Kinase Inhibitors - chemistry | Pyrazoles - chemistry | Lymphoma, B-Cell - enzymology | Autoimmune Diseases - drug therapy | Disease Models, Animal | Lymphoma, B-Cell - drug therapy | Pyrazoles - pharmacology | B-Lymphocytes - enzymology | Benzofurans - therapeutic use | Autoimmune Diseases - enzymology | Administration, Oral | Pyrimidines - administration & dosage | Treatment Outcome | Pyrimidines - pharmacology | Receptors, Antigen, B-Cell - immunology | B-Lymphocytes - drug effects | Protein Kinase Inhibitors - administration & dosage | Pyrazoles - administration & dosage | Animals | B-Lymphocytes - immunology | Signal Transduction - drug effects | Lymphocyte Activation - drug effects | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Dogs | Protein Kinase Inhibitors - pharmacology | Protein-Tyrosine Kinases - antagonists & inhibitors | Tyrosine | Cell receptors | Models | Lymphomas | Research | Properties | Biological Sciences
Journal Article
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 2/2012, Volume 109, Issue 8, pp. 2989 - 2994
Trimethylation of histone H3 on lysine 27 (H3K27me3) is a repressive posttranslational modification mediated by the histone methyltransferase EZH2. EZH2 is a... 
Tumor cell line | Substrate specificity | Cell lines | Stem cells | Histones | Methylation | Genetic mutation | Lymphoma | Cancer | Tumors | METHYLATION LEVELS | MODIFYING GENES | PROTEIN | HYPERMETHYLATION | MULTIDISCIPLINARY SCIENCES | PROSTATE-CANCER | GENE EZH2 | CARCINOMA | SOMATIC MUTATIONS | PRODUCT SPECIFICITY | HEMATOPOIETIC STEM | Transcription Factors - chemistry | Humans | Gene Expression Regulation, Neoplastic | Molecular Sequence Data | Substrate Specificity | Lymphoma, B-Cell - genetics | DNA-Binding Proteins - metabolism | Alanine - genetics | DNA Mutational Analysis | Base Sequence | Lymphoma, B-Cell - enzymology | Lysine - metabolism | Binding Sites | Glycine - genetics | Amino Acid Sequence | Histone-Lysine N-Methyltransferase - genetics | Mutant Proteins - metabolism | Transcription Factors - genetics | DNA-Binding Proteins - genetics | Mutation - genetics | DNA-Binding Proteins - chemistry | Enhancer of Zeste Homolog 2 Protein | Histone-Lysine N-Methyltransferase - chemistry | Transcription Factors - metabolism | Polycomb Repressive Complex 2 | Histone-Lysine N-Methyltransferase - metabolism | Mutant Proteins - chemistry | Cell Line, Tumor | Heterozygote | Histones - metabolism | Lymphocytic leukemia | Methyltransferases | Gene mutations | Lysine | Physiological aspects | Development and progression | Genetic aspects | Research | Health aspects | Biological Sciences
Journal Article
Nature Immunology, ISSN 1529-2908, 07/2007, Volume 8, Issue 7, pp. 705 - 714
Journal Article
Molecular Cell, ISSN 1097-2765, 11/2009, Volume 36, Issue 4, pp. 631 - 641
Journal Article
Journal Article
Cancer Research, ISSN 0008-5472, 06/2007, Volume 67, Issue 11, pp. 5408 - 5417
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2012, Volume 48, Issue 18, pp. 3319 - 3327
Abstract Background SF1126 is a peptidic pro-drug inhibitor of pan-PI3K/mTORC. A first-in-human study evaluated safety, dose limiting toxicities (DLT), maximum... 
Hematology, Oncology and Palliative Medicine | Pharmacodynamics | PI3K/mTORC pathway | SF1126 | Pharmacokinetics | Refractory solid tumours | B-cell malignancies | ACTIVATION | ANGIOGENESIS | PHOSPHATIDYLINOSITOL 3-KINASE | KINASE | GUIDELINES | CANCER | ONCOLOGY | PI3K PATHWAY | CHRONIC LYMPHOCYTIC-LEUKEMIA | INHIBITOR | ASSOCIATION | Humans | Middle Aged | Male | Neoplasm Proteins - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Oligopeptides - therapeutic use | Young Adult | Chromones - adverse effects | Aged, 80 and over | Antineoplastic Agents - pharmacokinetics | Chromones - pharmacology | Protein Kinase Inhibitors - pharmacokinetics | Lymphoma, Large B-Cell, Diffuse - drug therapy | Lymphoma, Large B-Cell, Diffuse - enzymology | Neoplasms - drug therapy | Protein Kinase Inhibitors - administration & dosage | Leukemia, Lymphocytic, Chronic, B-Cell - enzymology | Maximum Tolerated Dose | Oligopeptides - administration & dosage | TOR Serine-Threonine Kinases | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Oligopeptides - pharmacology | Proteins - antagonists & inhibitors | Prodrugs - administration & dosage | Multiprotein Complexes | Salvage Therapy | Chromones - administration & dosage | Molecular Targeted Therapy | Oligopeptides - adverse effects | Mechanistic Target of Rapamycin Complex 1 | Dose-Response Relationship, Drug | Antineoplastic Agents - adverse effects | Hypokalemia - chemically induced | Adult | Female | Antineoplastic Agents - pharmacology | Chromones - therapeutic use | Hematologic Diseases - chemically induced | Oligopeptides - pharmacokinetics | Neoplasms - enzymology | Chromones - pharmacokinetics | Prodrugs - adverse effects | Prodrugs - pharmacokinetics | Protein Kinase Inhibitors - therapeutic use | Aged | Prodrugs - therapeutic use | Protein Kinase Inhibitors - pharmacology | Infusions, Intravenous | Prodrugs - pharmacology | Gastrointestinal Diseases - chemically induced | Medicine, Experimental | Medical research | Care and treatment | Emergency medical services | Cancer | Index Medicus | PI3K | mTORC pathway
Journal Article